Compare Schwab US Large Cap Growth ETF (SCHG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs BIO-TECHNE Corp — how do they compare? Schwab US Large Cap Growth ETF trades at $36.65 (market cap $65.76B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 5.8× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Large Cap Growth ETF for 50 Days and BIO-TECHNE Corp for 63 Days on average.
| SCHG | TECH | |
|---|---|---|
Market Cap | $65.76B | $11.37B |
Volume | 8,114,853 | 3,153,511 |
Sector | Sector/Thematic | Health |
52-Week High | $36.93 | $72.61 |
52-Week Low | $28.10 | $43.31 |
Typical Hold Time | 50 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $36.87, down slightly by 0.16% today, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF maintains strong institutional interest despite recent position adjustments by some wealth managers. Recent media coverage highlights SCHG's low-cost growth exposure and historical performance advantages over broader market indices.
The outlook remains positive given SCHG's focus on large-cap growth stocks and competitive expense ratio, though concentration risk in top holdings and potential market volatility present challenges. Long-term growth prospects appear favorable based on historical returns and continued investor appetite for growth-oriented strategies.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
